Cuts both ways as risks being similar to Theranos with former secretaries of state types on their board. As was pointed out of the time the big question was who was on the science board and I think the same question applies here

>Also the company seems to be well-connected to the Trump-admin. Which I guess could be a good thing?

In terms of real-world results -- highly unlikely. In terms of funding - for sure.